Optimizing management of treatment-na&iuml;ve and treatment-experienced HIV+ patients: the role of maraviroc

Optimizing management of treatment-na&iuml;ve and treatment-experienced HIV+ patients: the role of maraviroc

Eva Poveda, Vincent SorianoDepartment of Infectious Diseases, Hospital Carlos III, Madrid, SpainAbstract: Maraviroc is the first CCR5 antagonist approved for the treatment of HIV-1 infection. It specifically inhibits the replication of R5 viruses by blocking viral entry. HIV-1 tropism can be estimat...

Full description

Bibliographic Details
Main Authors:	Eva Poveda, Vincent Soriano
Format:	Article
Language:	English
Published:	Dove Medical Press 2010-03-01
Series:	HIV/AIDS : Research and Palliative Care
Online Access:	http://www.dovepress.com/optimizing-management-of-treatment-naiumlve-and-treatment-experienced--a4111

Similar Items

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
by: Gonzalez-Serna A, et al.
Published: (2016-01-01)

Treatment of experienced and na&iuml;ve patients with hepatitis C: focus on telaprevir
by: D&#39;Ambrosio R, et al.
Published: (2012-10-01)

Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
by: Thore Lorenzen
Published: (2010-08-01)

Maraviroc (Celsentri) in HIV treatment
by: Viola Sacchi
Published: (2008-01-01)

Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-na&iuml;ve patients
by: Leo Flamholc, et al.
Published: (2008-12-01)

Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice
by: Reuter S, et al.
Published: (2010-06-01)

Effectiveness and cost of treatment with maraviroc in HIV infection
by: Viola Sacchi, et al.
Published: (2009-01-01)

An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients
by: Putcharoen O, et al.
Published: (2013-09-01)

Economic modeling in HIV for maraviroc in France in treatment experienced patients. Results from the ARAMIS 2011 model
by: Despiegel Nicolas, et al.
Published: (2012-05-01)

Canadian Consensus Guidelines for the Optimal Use of Maraviroc in the Treatment of HIV-Infected Adults
by: Anita Rachlis, et al.
Published: (2010-01-01)

Gut bacterial profile in patients newly diagnosed with treatment-na&iuml;ve Crohn&#39;s disease
by: Ricanek P, et al.
Published: (2012-09-01)

Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy
by: Corado KC, et al.
Published: (2018-11-01)

Maraviroc – a CCR5 antagonist for the treatment of HIV-1 infection
by: Elna eVan Der Ryst
Published: (2015-06-01)

Histopathological Pattern of Kidney Diseases Among HIV-Infected Treatment-Naïve Patients in Kano, Nigeria
by: Abdu A, et al.
Published: (2021-05-01)

Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens
by: A V Kravchenko
Published: (2013-11-01)

Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia
by: Knight T, et al.
Published: (2019-04-01)

HIV-1 Drug Resistance in ART-Naïve Individuals in Myanmar
by: Ye M, et al.
Published: (2020-04-01)

Increased burden and severity of metabolic syndrome and arterial stiffness in treatment naïve HIV+ patients from Cameroon
by: Ngatchou W, et al.
Published: (2013-09-01)

Magnitude of cytopenias among HIV‑infected children in Bahir Dar, northwest Ethiopia: a comparison of HAART-naïve and HAART‑experienced children
by: Tsegay YG, et al.
Published: (2017-02-01)

Maraviroc in Antiretroviral-Naïve HIV-1 Patients
by: Beniam Ghebremedhin
Published: (2012-01-01)

Maraviroc in Antiretroviral-Naïve HIV-1 Patients
by: Beniam Ghebremedhin
Published: (2012-01-01)

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
by: Restelli U, et al.
Published: (2017-06-01)

Undernutrition in ART-naïve Nigerian children
by: Shantakumari N, et al.
Published: (2015-07-01)

An observational study of bimatoprost 0.01% in treatment-na&iuml;ve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial
by: Nixon DR, et al.
Published: (2012-12-01)

Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B
by: Pacheco SR, et al.
Published: (2017-07-01)

Acceptability and efficacy of interactive short message service intervention in improving HIV medication adherence in Chinese antiretroviral treatment-naïve individuals
by: Ruan Y, et al.
Published: (2017-02-01)

Progressive multifocal leukoencephalopathy developing in a fludarabine na&iuml;ve patient with chronic lymphocytic leukemia
by: Melissa G Ooi, et al.
Published: (2009-01-01)

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
by: Jintanat Ananworanich, et al.
Published: (2015-04-01)

The role of etravirine in the management of treatment-experienced pediatric patients with HIV
by: Osterholzer D
Published: (2013-04-01)

First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease
by: Takahashi K, et al.
Published: (2020-09-01)

Fecal microbiota profiles in treatment-naïve pediatric inflammatory bowel disease – associations with disease phenotype, treatment, and outcome
by: Olbjørn C, et al.
Published: (2019-01-01)

Maraviroc: a review of its use in HIV infection and beyond
by: Woollard SM, et al.
Published: (2015-10-01)

The Discovery and Exploratory Development of Maraviroc (UK-427,857): A Novel CCR5 Antagonist for the Treatment of HIV
by: Hitchcock CA
Published: (2005-12-01)

Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.
by: Marilyn Lewis, et al.
Published: (2018-01-01)

V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1–infected, treatment-experienced persons receiving optimized background regimens
by: ME Lewis, et al.
Published: (2021-07-01)

Cortisol awakening response in drug-naïve panic disorder
by: Jakuszkowiak-Wojten K, et al.
Published: (2016-06-01)

Adherence to insulin treatment in insulin-naïve type 2 diabetic patients initiated on different insulin regimens
by: Gogas Yavuz D, et al.
Published: (2015-08-01)

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir
by: Michael Neely, et al.
Published: (2009-07-01)

Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials
by: Becky Jubb, et al.
Published: (2019-12-01)

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc.
by: Christophe Rodriguez, et al.
Published: (2015-01-01)

Cannot write session to /tmp/vufind_sessions/sess_60vs19bsefvvmsqcl4oluh1ft5